Canine Cushing’s Disease (Hyperadrenocorticism): Panting, Thirst, and Trilostane Care

Clinical presentation of Canine Cushing’s Disease (Hyperadrenocorticism): Panting, Thirst, and Trilostane Care requires immediate evaluation of baseline vital parameters and systemic stability. Veterinary assessment begins with a complete blood count, serum biochemistry, and urinalysis to establish metabolic function.

Clinical Quick Answer & Immediate Actions

Diagnosis and management require strict adherence to clinical protocols. Routine monitoring of vital signs, laboratory parameters, and behavioral indicators dictates therapeutic adjustments. Caregivers must utilize standardized tools to track disease progression objectively.

Diagnostic imaging, including thoracic radiography and abdominal ultrasonography, provides structural staging. Clients must monitor respiratory rate, mucous membrane color, and capillary refill time daily at home.

Pathophysiology and Clinical Progression

Disease progression alters metabolic pathways, increasing demands on hepatic and renal filtration systems. Cellular hypoxia and inflammatory cascades trigger secondary complications, necessitating multimodal therapeutic interventions.

Treatment focuses on restoring homeostatic balance through targeted pharmacological agents, dietary modification, and environmental stress reduction. Follow-up examinations at 14 and 30 days evaluate therapeutic efficacy and drug tolerability.

Medication administration requires strict adherence to prescribed intervals. Subtherapeutic dosing risks treatment failure, while exceeding recommended limits increases the probability of hepatic or renal toxicity.

Caregivers should record daily observations in a structured health journal, noting appetite fluctuations, elimination patterns, and behavioral shifts. This data directly informs subsequent veterinary dosage adjustments.

When to Seek Emergency Intervention

Immediate veterinary care is mandatory if the patient exhibits acute collapse, cyanotic mucous membranes, unremitting vomiting, or status epilepticus. Delaying transport during these critical windows significantly decreases survival probability.

Contact the emergency clinic prior to arrival to prepare the triage team. Provide current medication lists and time of last administration to expedite admission protocols.

Emergency Triage Matrix: Clinical Presentation & Required Response

Related Clinical Guides & Tools

Advanced Clinicopathologic Staging, Differential Workup & Long-Term Monitoring

Veterinary Pathophysiology of Canine Cushing’s Disease

Canine hyperadrenocorticism (HAC) results from chronic, excessive systemic exposure to glucocorticoids (primarily cortisol). It is broadly categorized into two primary forms:

• Pituitary-Dependent Hyperadrenocorticism (PDH): Accounts for ~80–85% of cases. A benign, functional pituitary adenoma (typically of the pars distalis or pars intermedia) secretes excess adrenocorticotropic hormone (ACTH), driving bilateral adrenal cortical hyperplasia (predominantly the zona fasciculata and zona reticularis).
• Adrenal-Dependent Hyperadrenocorticism (ADH): Accounts for ~15–20% of cases. A functional adrenocortical neoplasm (adenoma or carcinoma) autonomously secretes massive quantities of cortisol, leading to negative feedback that suppresses pituitary ACTH and causes atrophy of the contralateral, non-neoplastic adrenal gland.

Pathophysiological Mechanisms of Key Clinical Signs:

• Polydipsia (Thirst) and Polyuria (PU/PD): Excess glucocorticoids inhibit the release of antidiuretic hormone (ADH) from the posterior pituitary and competitively antagonize its action at the renal collecting ducts (inducing central-like and nephrogenic-like diabetes insipidus). This leads to primary polyuria, with compensatory polydipsia.
• Panting (Tachypnea/Respiratory Distress): Glucocorticoids induce catabolic loss of skeletal muscle mass (including intercostal muscles and the diaphragm), impairing respiratory mechanics. Excess cortisol also directly alters the thermoregulatory center in the hypothalamus, shifts metabolic rate, and can cause subclinical pulmonary thromboembolism or bronchial mineralization, culminating in resting tachypnea and excessive panting.

Clinicopathologic Staging & Laboratory Findings

Routine database anomalies in a patient with HAC reflect the metabolic footprint of chronic hypercortisolemia:

• Complete Blood Count (CBC):
• Stress Leukogram: Mature neutrophilia, lymphopenia, and eosinopenia (mediated by glucocorticoid-induced redistribution and apoptosis).
• Erythrocytosis: Mild polycythemia due to glucocorticoid-stimulated erythropoietin release or bone marrow stimulation.
• Serum Biochemistry Profile:
• Serum Alkaline Phosphatase (SAP): Markedly elevated. Corticosteroid-induced isoenzyme (CISAP) is highly specific for canine HAC, though hepatic enzyme leakage from glycogen hepatopathy also elevates standard ALP and ALT.
• Hyperglycemia: Mild to moderate fasting hyperglycemia driven by hepatic gluconeogenesis and peripheral insulin resistance (steroid hepatopathy/diabetes).
• Serum Cholesterol and Triglycerides: Frequently elevated due to altered lipid mobilization and metabolism.
• Electrolytes: Usually normal in PDH/ADH. Mild hyponatremia and hyperkalemia should prompt suspicion of atypical HAC, concurrent hypoadrenocorticism, or impending crisis (e.g., if on medical management).
• Urinalysis:
• Hyposthenuria or isosthenuria (urine specific gravity often ≤ 1.018).
• Proteinuria (urine protein-to-creatinine [UPC] ratio elevated due to systemic hypertension and glomerular damage).
• Concurrent urinary tract infection (UTI) is common even in the absence of pyuria, due to cortisol-induced immunosuppression. A urine culture is mandatory.

Differential Diagnosis for Canine Cushing’s Disease (Hyperadrenocorticism)

The clinical presentation of PU/PD, polyphagia, and panting has a broad differential. Diagnostic workups must rule out:

• Endocrinopathies: Diabetes mellitus, hypothyroidism (can overlap or mimic), and primary diabetes insipidus.
• Renal Disease: Chronic kidney disease (CKD) presenting with PU/PD (though CKD usually features azotemia and lower specific gravity, whereas HAC can occasionally concurrent).
• Hepatic or Gastrointestinal Disease: Chronic hepatitis or portosystemic vascular anomalies (elevated liver enzymes).
• Urinary Tract Pathologies: Primary urinary tract infections, pyelonephritis, or hypercalcemia of malignancy leading to secondary nephrogenic diabetes insipidus.
• Non-Adrenal Illnesses causing “Non-Adrenal Illness Hypercortisolemia” (Stress Leukogram/Euthyroid Sick): Any severe systemic illness can elevate baseline cortisol, necessitating specific screening tests (e.g., Low-Dose Dexamethasone Suppression test or ACTH Stimulation test) rather than single random cortisol measurements.

Trilostane Care & Pharmacologic Management

Trilostane is a competitive, reversible inhibitor of the 3β-hydroxysteroid dehydrogenase (3β-HSD) enzyme system in the adrenal cortex. This blocks the conversion of pregnenolone to progesterone, effectively halting the synthesis of cortisol, and to a lesser extent, aldosterone and sex steroids.

Initiation and Dosing:

• Administered orally, always with food at an individualized starting dose calculated by a veterinarian, with current consensus guidelines favoring dividing the veterinarian-calculated daily dose into twice-daily administration under a Standardized low-dose dexamethasone IV protocol and ACTH stimulation monitoring.
• Standard starting total daily dose ranges from 1 to 2 milligrams per kilogram body weight, divided either once daily or (more commonly favored by specialists to avoid “cortisol peaks and crashes”) twice daily at 1 milligrams per kilogram q12h.

Long-Term Management & Laboratory Monitoring

Patient monitoring is vital to prevent iatrogenic hypoadrenocorticism (Addisonian crisis) or persistent, uncontrolled hypercortisolemia.

Monitoring Modalities: for Canine Cushing’s Disease (Hyperadrenocorticism)

• Clinical Evaluation (The Cornerstone): Resolution or improvement of PU/PD, ravenous appetite, panting, and lethargy are the primary indicators of a successful therapeutic window.
• ACTH Stimulation Test: Historically and structurally standard. Performed 4 to 6 hours post-trilostane administration.
• Target Post-Stimulation Cortisol: Generally aimed between 1.5 and 5.0 µg/dL (40–150 nmol/L). Values < 1.5 µg/dL indicate potential over-suppression.
• Pre-Pill (Baseline) Cortisol Monitoring: Increasingly favored as a practical adjunct or alternative. Drawn immediately before the morning dose is administered. A pre-pill cortisol level between 1.0 and 3.0 µg/dL typically correlates well with good clinical control, though any signs of lethargy, anorexia, vomiting, or diarrhea warrant immediate discontinuation and electrolyte assessment, regardless of lab values.

Monitoring Schedule: for Canine Cushing’s Disease (Hyperadrenocorticism)

• Initial check at 10–14 days post-initiation (or post-dose adjustment).
• Repeat at 30 days, 90 days, and then every 3 to 6 months lifelong.
• Concurrent tracking of serum electrolytes (sodium/potassium) and renal parameters is essential during monitoring checks to catch early mineralocorticoid deficiency (hypoadrenocorticism).